Inhibrx, Inc.
(NASDAQ : INBX)

( )
INBX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.21%212.040.0%$1971.46m
BIIBBiogen, Inc. -0.67%371.901.7%$1288.80m
NVAXNovavax, Inc. -1.10%192.2479.8%$820.37m
SNSSSunesis Pharmaceuticals, Inc. -5.76%11.130.7%$778.03m
AMGNAmgen, Inc. -0.50%238.711.3%$637.40m
BNTXBioNTech SE -2.96%229.500.0%$572.94m
VRTXVertex Pharmaceuticals, Inc. -0.72%187.521.9%$527.63m
GILDGilead Sciences, Inc. -0.60%66.651.0%$475.82m
REGNRegeneron Pharmaceuticals, Inc. -0.79%529.802.7%$386.12m
ILMNIllumina, Inc. 0.74%469.133.5%$346.93m
OCGNOcugen, Inc. 2.02%7.560.0%$345.77m
ALXNAlexion Pharmaceuticals, Inc. 0.11%179.832.0%$331.72m
TXG10X Genomics, Inc. 2.16%201.410.0%$178.72m
EXASEXACT Sciences Corp. 2.37%130.9718.1%$176.05m
BNGOBionano Genomics, Inc. 1.68%7.250.0%$156.12m

Company Profile

Inhibrx, Inc. is a biotechnology company. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.